Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a model disease for the use of targeted pharmaceuticals in thoracic oncology. This entry summarizes the state-of-the-art treatment for these tumors as of January 2021, with a special emphasis in the sequential use of various compounds as well as the growing importance of molecular profiling and monitoring for patient management.